What is the recommended management for a patient with markedly elevated C‑reactive protein and erythrocyte sedimentation rate and CT evidence of ostial‑proximal arterial involvement?

Immediate High-Dose Glucocorticoid Therapy with Tocilizumab

For a patient with markedly elevated inflammatory markers (CRP 272, ESR 76) and CT evidence of ostial-proximal arterial involvement, initiate high-dose oral glucocorticoids (40-60 mg prednisone daily) immediately with tocilizumab as adjunctive therapy. This presentation is consistent with large vessel vasculitis (likely giant cell arteritis with large vessel involvement or Takayasu arteritis), and the combination therapy provides superior outcomes compared to glucocorticoids alone 1.

Diagnostic Considerations

Your patient's presentation strongly suggests large vessel vasculitis:

• Markedly elevated inflammatory markers: CRP of 272 mg/L and ESR of 76 mm/hr are highly elevated and support active vasculitis 2, 3
• Ostial-proximal involvement: CT showing involvement of vessel origins (ostia) and proximal segments is characteristic of large vessel vasculitis 4

The combination of these findings warrants immediate treatment even before completing all diagnostic workup, as delays risk irreversible vascular complications 1.

Initial Treatment Algorithm

1. Immediate Glucocorticoid Initiation

• Start prednisone 40-60 mg daily (oral route is acceptable unless cranial ischemic symptoms present) 1
• If visual symptoms, diplopia, or stroke risk: use IV methylprednisolone 500-1000 mg daily for 3 days first 1
• Daily dosing is superior to alternate-day schedules 1

2. Add Tocilizumab Immediately

The 2021 ACR/Vasculitis Foundation guidelines strongly recommend high-dose glucocorticoids WITH tocilizumab over glucocorticoids alone for newly diagnosed GCA 1. This is particularly important given:

• Your patient has large vessel involvement (higher relapse risk)
• Combination therapy reduces glucocorticoid exposure and toxicity
• Superior remission rates compared to monotherapy

3. Complete Diagnostic Workup

While treating, obtain:

• Temporal artery biopsy if GCA suspected (can be done up to 2 weeks after starting steroids) 1
• Complete vascular imaging: MR or CT angiography of neck/chest/abdomen/pelvis to map all large vessel involvement 1, 4
• Rule out infections before attributing elevated markers solely to vasculitis 4

Glucocorticoid-Sparing Strategy

The goal is rapid taper to minimize toxicity:

• Weeks 1-4: Maintain high dose (40-60 mg daily)
• Months 2-6: Taper gradually based on clinical response and inflammatory markers
• Target: Reach ≤10 mg/day by 6 months with tocilizumab support 1

Methotrexate can be considered if tocilizumab is unavailable or contraindicated, though it is less effective 1, 4.

Monitoring Strategy

Clinical Assessment

• Weekly initially, then monthly once stable
• Monitor for: new headaches, visual changes, jaw/limb claudication, constitutional symptoms
• Do not rely solely on ESR/CRP: Inflammatory markers may remain elevated despite clinical remission, especially on imaging 4

Laboratory Monitoring

• ESR and CRP every 2-4 weeks initially
• Important caveat: Isolated rises in ESR/CRP without symptoms should NOT automatically trigger treatment escalation—rule out infection first 4

Imaging Follow-up

• Repeat vascular imaging at 3-6 months to assess for progression, aneurysm formation, or new stenoses 1, 4
• Persistent vessel wall inflammation on imaging may represent remodeling rather than active disease 4

Glucocorticoid Toxicity Prevention

Initiate immediately:

• Calcium 1200-1500 mg daily + Vitamin D 800-1000 IU
• Bisphosphonate therapy (alendronate or risedronate)
• Proton pump inhibitor or H2-blocker
• Pneumocystis prophylaxis if prednisone >20 mg daily for >1 month
• Monitor for: hyperglycemia, hypertension, infections, osteoporosis 5

Relapse Management

If relapse occurs despite treatment:

Major Relapse (ischemic symptoms or progressive vascular inflammation)

• Reinstitute high-dose glucocorticoids (40-60 mg daily) 4
• Escalate or switch immunosuppression: Consider TNF-inhibitor if already on tocilizumab 4

Minor Relapse (constitutional symptoms only)

• Increase prednisone to last effective dose or 5-15 mg above current dose 4
• Consider adding/switching adjunctive agent 1

Critical Pitfalls to Avoid

1. Do not delay treatment waiting for biopsy—start immediately with this degree of inflammation and vascular involvement
2. Do not use glucocorticoids alone when tocilizumab is available—combination is superior 1
3. Do not chase inflammatory markers alone—clinical assessment is paramount 4
4. Do not ignore glucocorticoid prophylaxis—toxicity is nearly universal with prolonged high-dose therapy 5
5. Do not assume normal ESR/CRP rules out active disease—4% of GCA patients have normal markers at diagnosis 2